At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Dr. Meijing Wu is described by friends and colleagues as a distinguished biostatistician and “a kind and generous friend who ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

Scientists at UMC Utrecht have developed a new technology to efficiently isolate a specific subset of gut bacteria from fecal ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

There’s a big ol’ leak in Abbvie’s drug development pipeline. On Monday, the pharma giant announced that two mid-stage trials ...